1000 related articles for article (PubMed ID: 32393771)
1. Pancreatic cancer stroma: an update on therapeutic targeting strategies.
Hosein AN; Brekken RA; Maitra A
Nat Rev Gastroenterol Hepatol; 2020 Aug; 17(8):487-505. PubMed ID: 32393771
[TBL] [Abstract][Full Text] [Related]
2. Stroma-targeting strategies in pancreatic cancer: a double-edged sword.
Liu X; Iovanna J; Santofimia-Castaño P
J Physiol Biochem; 2023 Feb; 79(1):213-222. PubMed ID: 36580230
[TBL] [Abstract][Full Text] [Related]
3. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
4. A bioprinted sea-and-island multicellular model for dissecting human pancreatic tumor-stroma reciprocity and adaptive metabolism.
Li M; Freeman S; Franco-Barraza J; Cai KQ; Kim A; Jin S; Cukierman E; Ye K
Biomaterials; 2024 Oct; 310():122631. PubMed ID: 38815457
[TBL] [Abstract][Full Text] [Related]
5. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.
Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA
Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930
[TBL] [Abstract][Full Text] [Related]
6. Fibrosis and cancer: A strained relationship.
Piersma B; Hayward MK; Weaver VM
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188356. PubMed ID: 32147542
[TBL] [Abstract][Full Text] [Related]
7. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting.
Vaish U; Jain T; Are AC; Dudeja V
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948209
[TBL] [Abstract][Full Text] [Related]
8. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer.
McAndrews KM; Chen Y; Darpolor JK; Zheng X; Yang S; Carstens JL; Li B; Wang H; Miyake T; Correa de Sampaio P; Kirtley ML; Natale M; Wu CC; Sugimoto H; LeBleu VS; Kalluri R
Cancer Discov; 2022 Jun; 12(6):1580-1597. PubMed ID: 35348629
[TBL] [Abstract][Full Text] [Related]
9. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
Yu Y; Schuck K; Friess H; Kong B
Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
11. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
[TBL] [Abstract][Full Text] [Related]
12. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
13. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
14. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
15. The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis.
Barrera LN; Ridley PM; Bermejo-Rodriguez C; Costello E; Perez-Mancera PA
J Physiol Biochem; 2023 Feb; 79(1):193-204. PubMed ID: 35767180
[TBL] [Abstract][Full Text] [Related]
16. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer.
Pereira BA; Vennin C; Papanicolaou M; Chambers CR; Herrmann D; Morton JP; Cox TR; Timpson P
Trends Cancer; 2019 Nov; 5(11):724-741. PubMed ID: 31735290
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities.
Qin Q; Yu R; Eriksson JE; Tsai HI; Zhu H
Cancer Lett; 2024 Jun; 591():216859. PubMed ID: 38615928
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer.
Dings MPG; Manoukian P; Waasdorp C; Quik JSE; Strijker M; Lodestijn SC; van Neerven SM; Moreno LF; de Oliveira RL; Bonsing BA; Bruno MJ; Busch OR; Doukas M; van Eijck CH; Mohammad NH; de Hingh IH; Molenaar QI; Besselink MG; Vermeulen L; Medema JP; van Laarhoven HWM; Bijlsma MF
Int J Cancer; 2023 Feb; 152(3):511-523. PubMed ID: 36069222
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor.
Yang HH; Liu JW; Lee JH; Harn HJ; Chiou TW
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360896
[TBL] [Abstract][Full Text] [Related]
20. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.
Moatassim-Billah S; Duluc C; Samain R; Jean C; Perraud A; Decaup E; Cassant-Sourdy S; Bakri Y; Selves J; Schmid H; Martineau Y; Mathonnet M; Pyronnet S; Bousquet C
Oncotarget; 2016 Jul; 7(27):41584-41598. PubMed ID: 27177087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
